BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30043237)

  • 1. Activity of rheumatoid arthritis correlates with oral inflammatory burden.
    Äyräväinen L; Heikkinen AM; Kuuliala A; Ahola K; Koivuniemi R; Peltola J; Suomalainen A; Moilanen E; Hämäläinen M; Laasonen L; Meurman JH; Leirisalo-Repo M
    Rheumatol Int; 2018 Sep; 38(9):1661-1669. PubMed ID: 30043237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.
    Äyräväinen L; Leirisalo-Repo M; Kuuliala A; Ahola K; Koivuniemi R; Meurman JH; Heikkinen AM
    BMJ Open; 2017 Jan; 7(1):e011916. PubMed ID: 28143836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
    Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory biomarkers in saliva and serum of patients with rheumatoid arthritis with respect to periodontal status.
    Äyräväinen L; Heikkinen AM; Kuuliala A; Ahola K; Koivuniemi R; Laasonen L; Moilanen E; Hämäläinen M; Tervahartiala T; Meurman JH; Leirisalo-Repo M; Sorsa T
    Ann Med; 2018 Jun; 50(4):333-344. PubMed ID: 29683364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis.
    Kuusela E; Kouri VP; Olkkonen J; Koivuniemi R; Äyräväinen L; Rajamäki K; Valleala H; Nordström D; Leirisalo-Repo M; Ainola M; Eklund KK
    Clin Exp Rheumatol; 2018; 36(5):778-784. PubMed ID: 29600942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.
    Jurgens MS; Overman CL; Jacobs JW; Geenen R; Cuppen BV; Marijnissen AC; Bijlsma JW; Welsing PM; Lafeber FP; van Laar JM;
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):923-8. PubMed ID: 25504811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
    Mueller RB; Reshiti N; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; Schiff M; Spaeth M; von Kempis J;
    Clin Rheumatol; 2017 Jan; 36(1):59-66. PubMed ID: 27838788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.
    Durán J; Combe B; Niu J; Rincheval N; Gaujoux-Viala C; Felson DT
    Rheumatology (Oxford); 2015 Dec; 54(12):2166-70. PubMed ID: 26175470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
    Amoruso A; Sola D; Rossi L; Obeng JA; Fresu LG; Sainaghi PP; Pirisi M; Brunelleschi S
    Pharmacol Res; 2016 May; 107():308-314. PubMed ID: 27045818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
    Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
    Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
    Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.